rajasekharkakarla
☆    

India,
2019-09-20 08:35
(1652 d 06:08 ago)

Posting: # 20628
Views: 1,740
 

 Reference replicated designs [Regulatives / Guidelines]

Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
105 visitors (0 registered, 105 guests [including 5 identified bots]).
Forum time: 13:44 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5